Corporate Development     

Published: September 15, 2025
Updated: September 15, 2025

Biocon New Jersey Plant Gets USFDA Approval

Biocon, a Bangalore-headquartered company publicly listed since 2004 recently announced the inauguration of its first US manufacturing facility in Cranbury, New Jersey, by its wholly owned subsidiary, Biocon Generics Inc (BGI). The Governor of New Jersey, Phil Murphy, was the guest of honour at the inauguration.

The company acquired the Oral Solid Dosage (OSD) facility from Eywa Pharma Inc in 2023 and has since invested over $ 30 million to establish a state-of-the-art plant with an annual production capacity of 2 billion tablets. A few products have already been commercialized from the site, with several more in the pipeline. This investment helps Biocon diversify its manufacturing base, strengthen its supply chain and accelerate the expansion of its global footprint.

The Cranbury facility represents a strategic advancement for the company’s US operations, enabling faster access to essential therapies, enhanced supply reliability, and a stronger connection with partners and healthcare providers, ultimately benefiting patients across the US.

‘NEW CHAPTER’

Kiran Mazumdar-Shaw, Chairperson, Biocon group, said, “Biocon’s first USFDA-approved formulations facility in New Jersey marks a new chapter in our journey of global expansion. More than a milestone, it is a reaffirmation of our purpose to serve patients wherever they are. Governor Phil Murphy’s presence at the inauguration highlights the importance of Biocon’s role in fostering innovation, creating job opportunities, and strengthening the US healthcare ecosystem. This facility reflects our long-term commitment to building a healthier and equitable future.”

Siddharth Mittal, Chief Executive Officer and Managing Director, Biocon, commented, “This strategic investment brings us closer to patients, healthcare providers and partners in this important market. The proximity allows us to deliver our vertically integrated, high-quality medicines more efficiently to patients across the United States and other markets, ensuring supply chain resilience and enabling us to advance our mission of expanding access to affordable therapies worldwide.”

BIOPHARMA LEADER

Biocon is an innovation-led global biopharmaceutical company committed to enhancing affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars and complex small molecule APIs in India and several key global markets, as well as generic formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development.